Short answer
Harmony Biosciences Holdings, Inc. (HRMY) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $269M (up 12.3% year over year) with net income of $48M.
Q3 2026 key financials · XBRL
- Revenue
- $269M
- +12.3% YoY · +2.9% QoQ
- Net income
- $48M
- −5.2% YoY · −36.1% QoQ
- Operating margin
- 20.2%
- Gross margin
- 70.0%
- EPS (diluted)
- $0.79
- −8.1% YoY · −38.8% QoQ
Source: XBRL data from the Harmony Biosciences Holdings, Inc. (HRMY) Q3 2026 10-Q on SEC EDGAR. USD.
Harmony Biosciences Holdings, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $268.9M, up 12.3% YoY from $239.5M, driven by 7.5% higher units and a 7% price increase
- Gross margin 70.0% vs 75.1% YoY, with cost of product sold rising to 30.0% of revenue from 24.9%
- WAKIX, the sole commercial product, averaged approximately 9,350 patients; formulary access exceeded 80% of insured lives
- Operating cash flow $196.9M year-to-date vs $222.0M, with $307.5M investing outflow including $369.9M debt-security purchases
- Cash, equivalents and investments $1,052.0M; management expects funding for operational needs and potential investments for at least 12 months
Risk Factors
- No material changes to 2025 Form 10-K risk factors as of September 30, 2026
- Previously disclosed risks may materially affect business, financial condition, or operating results
- Unknown or currently immaterial risks could materially adversely affect results
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Harmony Biosciences Holdings, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.